Vertex’s Orkambi Approved With Broad Label For Cystic Fibrosis
This article was originally published in The Pink Sheet Daily
Executive Summary
Quick launch is planned, with firm having prepared ‘at risk of having a successful approval’ – patient screening and reimbursement shepherding are early areas of focus.
You may also be interested in...
New CDER Lab Will Help Push Advanced Manufacturing Adoption
US FDA plans to open a manufacturing research lab near its White Oak headquarters in 2021 to facilitate evaluation of novel manufacturing technology.
Cystic Fibrosis Drug Sales Should Soar; VX-661/Ivacaftor To Lead Way
Sales of key cystic fibrosis drugs will jump in western economies over the next decade, driven by strong uptake of high-cost CFTR modulator therapies and longer use as life expectancies improve, according to a new report by Datamonitor Healthcare.
Vertex's VX-661 Has Positive Outlook Despite Futility Finding
Although a study testing a combo of the company's cystic fibrosis drug Kalydeco and the investigational VX-661 in patients with minimal CFTR function was ended due to futility, Vertex is on pace for a 2017 filing of the combo in three other CF subpopulations.